Biologic therapies versus surgical management for aspirin-exacerbated respiratory disease: A review of preliminary data, efficacy, and cost

Aspirin-exacerbated respiratory disease (AERD) patients with CRSwNP suffer from reduced quality of life, reduced economic productivity, and higher risk of depression and sleep dysfunction. These patients often require frequent medical and surgical therapy, including functional endoscopic sinus surge...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Alan D. Workman, Benjamin S. Bleier
Formato:	article
Lenguaje:	EN
Publicado:	KeAi Communications Co., Ltd. 2020
Materias:	CRSwNP AERD Biologics Omalizumab Dupilumab Otorhinolaryngology RF1-547 Surgery RD1-811
Acceso en línea:	https://doaj.org/article/7783b942a26d4f468872f81983e19fd7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7783b942a26d4f468872f81983e19fd7
record_format	dspace
spelling	oai:doaj.org-article:7783b942a26d4f468872f81983e19fd72021-12-02T18:12:37ZBiologic therapies versus surgical management for aspirin-exacerbated respiratory disease: A review of preliminary data, efficacy, and cost2095-881110.1016/j.wjorl.2020.06.002https://doaj.org/article/7783b942a26d4f468872f81983e19fd72020-12-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2095881120300767https://doaj.org/toc/2095-8811Aspirin-exacerbated respiratory disease (AERD) patients with CRSwNP suffer from reduced quality of life, reduced economic productivity, and higher risk of depression and sleep dysfunction. These patients often require frequent medical and surgical therapy, including functional endoscopic sinus surgery for recalcitrant disease. Given this severity, anti-type 2 biologic treatments are being investigated for use in this subgroup of patients with CRSwNP, including Omalizumab and Dupilumab. Preliminary data suggests that SNOT-22 related quality of life improvements following treatment with biologics are comparable to the current standard of care in the short term, but there is a lack of long-term data and standardized regimen that makes direct comparison difficult. Biologic therapies additionally require continuous use to avoid recurrence, and currently cost many times more than existing medical or surgical therapies.Alan D. WorkmanBenjamin S. BleierKeAi Communications Co., Ltd.articleCRSwNPAERDBiologicsOmalizumabDupilumabOtorhinolaryngologyRF1-547SurgeryRD1-811ENWorld Journal of Otorhinolaryngology-Head and Neck Surgery, Vol 6, Iss 4, Pp 230-234 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	CRSwNP AERD Biologics Omalizumab Dupilumab Otorhinolaryngology RF1-547 Surgery RD1-811
spellingShingle	CRSwNP AERD Biologics Omalizumab Dupilumab Otorhinolaryngology RF1-547 Surgery RD1-811 Alan D. Workman Benjamin S. Bleier Biologic therapies versus surgical management for aspirin-exacerbated respiratory disease: A review of preliminary data, efficacy, and cost
description	Aspirin-exacerbated respiratory disease (AERD) patients with CRSwNP suffer from reduced quality of life, reduced economic productivity, and higher risk of depression and sleep dysfunction. These patients often require frequent medical and surgical therapy, including functional endoscopic sinus surgery for recalcitrant disease. Given this severity, anti-type 2 biologic treatments are being investigated for use in this subgroup of patients with CRSwNP, including Omalizumab and Dupilumab. Preliminary data suggests that SNOT-22 related quality of life improvements following treatment with biologics are comparable to the current standard of care in the short term, but there is a lack of long-term data and standardized regimen that makes direct comparison difficult. Biologic therapies additionally require continuous use to avoid recurrence, and currently cost many times more than existing medical or surgical therapies.
format	article
author	Alan D. Workman Benjamin S. Bleier
author_facet	Alan D. Workman Benjamin S. Bleier
author_sort	Alan D. Workman
title	Biologic therapies versus surgical management for aspirin-exacerbated respiratory disease: A review of preliminary data, efficacy, and cost
title_short	Biologic therapies versus surgical management for aspirin-exacerbated respiratory disease: A review of preliminary data, efficacy, and cost
title_full	Biologic therapies versus surgical management for aspirin-exacerbated respiratory disease: A review of preliminary data, efficacy, and cost
title_fullStr	Biologic therapies versus surgical management for aspirin-exacerbated respiratory disease: A review of preliminary data, efficacy, and cost
title_full_unstemmed	Biologic therapies versus surgical management for aspirin-exacerbated respiratory disease: A review of preliminary data, efficacy, and cost
title_sort	biologic therapies versus surgical management for aspirin-exacerbated respiratory disease: a review of preliminary data, efficacy, and cost
publisher	KeAi Communications Co., Ltd.
publishDate	2020
url	https://doaj.org/article/7783b942a26d4f468872f81983e19fd7
work_keys_str_mv	AT alandworkman biologictherapiesversussurgicalmanagementforaspirinexacerbatedrespiratorydiseaseareviewofpreliminarydataefficacyandcost AT benjaminsbleier biologictherapiesversussurgicalmanagementforaspirinexacerbatedrespiratorydiseaseareviewofpreliminarydataefficacyandcost
_version_	1718378516822622208

Biologic therapies versus surgical management for aspirin-exacerbated respiratory disease: A review of preliminary data, efficacy, and cost

Ejemplares similares